Note: Ingredients listed on restricted chemical lists
EC/CAS
247-852-1/26628-22-8
Name of the chemical
Sodium Azide
Concentration
<0.1%
EC/CAS
200-580-7/64-19-7
Name of the chemical
acetic acid
Concentration
<0.1%
General Information
Version
2,0 - Replaces version 1,1
Revision date
2023-08-22
Product name
Eosin 1 %, aqueous
1.2.1 Relevant identified uses
Staining tissue samples, Use as laboratory reagent The product is intended for research, analysis and scientific education
Emergency telephone
+49(0)6131/19240
Icons in SDS
Company Information
company name
SLEE medical GmbH
e-mail address of the competent person responsible for the Safety Data Sheet
mail@slee.de
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Classification of the substance or mixture GB CLP Regulation Skin Sens. 1; H317 Full text of hazard statements: see SECTION 16
2.2 Label elements
GB CLP Regulation
Hazardous Ingredients
Eosin G
Signal word
Warning
Hazard statements
H317 May cause an allergic skin reaction.
Precautionary statements
P261 Avoid breathing Vapour. P280 Wear protective gloves/protective clothing/eye protection/face protection. P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulating and toxic (PBT) or very persistent and very bioaccumulating (vPvB) at levels of 0.1% or higher. Ecological information: The substance/mixture does not contain any components that are considered to be hazardous according to REACH Article 57(f) or Commission Delegated Regulation (EU) 2017/2100 or Commission Delegated Regulation (EU) 2018/605 in amounts of 0.1 % or more have endocrine disrupting properties. Toxicological information: The substance/mixture does not contain any components that are to be classified according to REACH Article 57(f) or Commission Delegated Regulation (EU) 2017/2100 or Commission Delegated Regulation (EU) 2018/605 in quantities of 0.1 % or more have endocrine disrupting properties.
2.1 Classification of the substance or mixture
GB CLP Regulation Skin Sens. 1; H317 Full text of hazard statements: see SECTION 16.
